Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light

With obesity widespread, undertreated and largely misunderstood, Novo Nordisk has been gunning to overhaul the field with semaglutide, a drug originally approved to treat diabetes. On Friday, it won its coveted FDA green light in obesity.